Merck KGaA, Darmstadt, Germany, Appoints Thomas Möller as new Head of External Communications
Darmstadt, Germany, December 8, 2016 – Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that Thomas Möller (40) has been appointed Head of External Communications at Merck KGaA, Darmstadt, Germany, effective January 1, 2017. He will report to Isabel De Paoli, Head of Group Communications. Möller succeeds Nicole Mommsen who has left the company end of September at her own request.
Thomas Möller joins from BASF where he held a variety of communications functions in Germany, the United States and Switzerland. Among other things, he had been in charge of Media Relations Europe and the Global Competence Center Crisis Communications.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck KGaA, Darmstadt, Germany, generated sales of € 12.85 billion in 66 countries.
Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the „Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Two new strategic drug discovery collaborations aim at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities.